AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8267679
Drug: Bromfenac 75
RxNorm normalized name: bromfenac 0.75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac 75 mg
Trial: 3009726
Drug: Postoperative CAP
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative CAP chemotherapy (Cytoxan, Adriamycin, and cisplatin)
Trial: 7988247
Drug: Bacillus Calmette‐Guerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette‐Guerin (BCG) and levamisole immunotherapy
Trial: 24604243
Drug: Ketoconazole 400
RxNorm normalized name: ketoconazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 400 mg once daily for 14 days
Trial: 24604243
Drug: Diltiazem 300
RxNorm normalized name: diltiazem 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 300 mg once daily for 11 days
Trial: 22313564
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo solution
Trial: 15635348
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg of S oblonga extract
Trial: 15635348
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg of S oblonga extract (control)
Trial: 12131561
Drug: Lacidipine 4
RxNorm normalized name: lacidipine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine 4 mg o.i.d.
Trial: 10958373
Drug: 6.9% carbohydrate-electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.9% carbohydrate-electrolyte solution (CES)
Trial: 1748537
Drug: Film-coated tablet
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film-coated tablet
Trial: 1610425
Drug: New enteric-coated
RxNorm normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New enteric-coated pellet preparation
Trial: 23505172
Drug: Metformin (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2,000 mg/d)
Trial: 30497904
Drug: SB spray
RxNorm normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB spray
Trial: 30107350
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg intravenous (IV) ketamine
Trial: 23082557
Drug: Nevirapine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine (400 mg/day)
Trial: 23082557
Drug: Efavirenz (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz (600 mg/day)
Trial: 18626267
Drug: Citalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (10 mg/d)
Trial: 18626267
Drug: Clomipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (25 mg/d)
Trial: 18626267
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment groups (Citalopram and Clomipramine)
Trial: 10331828
Drug: Ceftazidime treatment
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime treatment (postintervention)
Trial: 10331828
Drug: Ceftazidime treatment
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime treatment (preintervention)
Trial: 7490172
Drug: Intra-articular injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injections of 750 mcg of somatostatin 14 (SST14) at 15-day intervals
Trial: 7490172
Drug: Intra-articular injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injections of 750 mcg of somatostatin 14 (SST14)
Trial: 25455003
Drug: Fostamatinib 100
RxNorm normalized name: fostamatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib 100 mg bid
Trial: 23378467
Drug: Fostamatinib 100
RxNorm normalized name: fostamatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib 100 mg qd
Trial: 15943851
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of famotidine (40 mg/day)
Trial: 15943851
Drug: Drip infusion
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drip infusion of omeprazole (40 mg/day)
Trial: 12600912
Drug: Acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (600 mg BID)
Trial: 10846331
Drug: 800 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 micrograms misoprostol vaginally at home (self-administered)
Trial: 9387637
Drug: Placebo medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medicine (Control)
Trial: 6481116
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of prednisone (oral dose)
Trial: 24367796
Drug: Biological male
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological male personnel
Trial: 23117776
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg dexamethasone
Trial: 20227579
Drug: Long-pulsed neodymium:yttrium-aluminium-garnet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-pulsed neodymium:yttrium-aluminium-garnet laser treatment
Trial: 20227579
Drug: Topical benzoyl
RxNorm normalized name: benzoyl peroxide Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzoyl peroxide and clindamycin (Control)
Trial: 12181386
Drug: Prednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (30 mg daily for 1 week)
Trial: 1951997
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg suxamethonium
Trial: 1951997
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg suxamethonium
Trial: 7019782
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release indomethacin capsules
Trial: 7019782
Drug: Oral route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral route of medication (sustained release indomethacin)
Trial: 31451704
Drug: Rice bran
RxNorm normalized name: Rice bran
DrugBank: Rice bran (DB14361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice bran extract supplement (RBS) 1,000 mg/day
Trial: 27523583
Drug: DASH diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DASH diet among participants with baseline serum UA ≥7 mg/dl (n=8)
Trial: 24366395
Drug: Heart failure
RxNorm normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart failure drugs (β-blockers, diuretics, ACEIs/ARBs)
Trial: 22484777
Drug: Beta-blockade (BB)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockade (BB) therapy
Trial: 8913402
Drug: Emla cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emla cream (5%)
Trial: 6341350
Drug: Cefotetan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (1 or 2 g every 12 h)
Trial: 6341350
Drug: Cefoxitin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (1 or 2 g every 8 h)
Trial: 28722480
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro (Ly-Lis)
Trial: 24957256
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg daily plus best supportive care (BSC)
Trial: 14658584
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with platinum analogues
Trial: 14658584
Drug: Various combinations
RxNorm normalized name: various combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various combinations of cytostatic drugs
Trial: 9061681
Drug: Treated bednets
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treated bednets (lambdacyhalothrin 10 mg/m2)
Trial: 8117508
Drug: Follow-up scintimetry
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up scintimetry after conservative treatment and osteosynthesis
Trial: 4027120
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal 50 g in 300 ml of water
Trial: 4027120
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal 50 g administered immediately after PAS 10 g or 20 g
Trial: 29917069
Drug: 0 µg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 µg/d vitamin D3
Trial: 29917069
Drug: 10 µg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg/d vitamin D3
Trial: 29917069
Drug: 20 µg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg/d vitamin D3
Trial: 27089843
Drug: Parenteral nutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutritional support for 5 days (n=1200)
Trial: 7475658
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg primaquine base daily (double‐blinded)
Trial: 7475658
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg chloroquine base weekly (open)
Trial: 1942917
Drug: Solcoseryl ophthalmic
RxNorm normalized name: Solcoseryl
DrugBank: Solcoseryl (DB15794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solcoseryl ophthalmic gel
Trial: 1942917
Drug: 2.4% cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4% cysteine in ophthalmic gel
Trial: 31180833
Drug: Hybrid robotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid robotic system combining EMG-Triggered FES with a passive exoskeleton for upper limb suspension during a structured exercise program of 27 sessions lasting 30 min each.
Trial: 28326680
Drug: Desmopressin 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin 0.3 μg/kg administered 30 min before surgery
Trial: 28326680
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administered 30 min before surgery
Trial: 25007542
Drug: Active light
RxNorm normalized name: Ensure Active Light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active light treatment (ALT)
Trial: 25007542
Drug: Placebo light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo light treatment (L-PBO)
Trial: 15023808
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/d for 6 weeks, then 80 mg/d for 6 weeks, then 80 mg/d for 24 weeks
Trial: 15023808
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/d for 6 weeks, then 40 mg/d for 6 weeks, then 80 mg/d for 24 weeks
Trial: 9280743
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (prepidil gel) plus oxitocin
Trial: 9280743
Drug: Intravenous oxitocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxitocin
Trial: 8397562
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 mg oral dose)
Trial: 8397562
Drug: Terbutaline (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (subcutaneous injection)
Trial: 31094286
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of UCVA and NCAR
Trial: 27452202
Drug: Alirocumab (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (75 mg every 2 weeks, increased to 150 mg if week 8 LDL-C ≥2.6/3.1 mmol/L)
Trial: 22082200
Drug: Sustained-release oxycodone
RxNorm normalized name: oxycodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release oxycodone tablets (initial dose of 10mg orally every 12 hours, titrated according to pain intensity)
Trial: 22082200
Drug: Sustained-release oxycodone
RxNorm normalized name: oxycodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release oxycodone tablets
Trial: 19329063
Drug: Boston Simplus
RxNorm normalized name: CONTACT LENS SOLN (BOSTON SIMPLUS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boston Simplus (Bausch & Lomb) multipurpose solution
Trial: 17454160
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (E2)/norethisterone acetate (NETA) (50 microg E2 daily for 14 days followed by 50 microg E2/0.25 microg NETA daily for 14 days; transdermal group, n = 19)
Trial: 17454160
Drug: Transdermal continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal continuous E2/oral medroxyprogesterone acetate (MPA) (50 microg E2/5 mg MPA daily; transdermal/oral group, n = 19)
Trial: 17454160
Drug: Oral continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral continuous E2/NETA (1 mg E2/0.5 mg NETA daily; oral group, n = 21)
Trial: 17454160
Drug: Subcutaneous fat
RxNorm normalized name: Sus scrofa subcutaneous fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous fat <33 mm (n = 29)
Trial: 17454160
Drug: Subcutaneous fat
RxNorm normalized name: Sus scrofa subcutaneous fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous fat >=33 mm (n = 30)
Trial: 14962821
Drug: Rifapentine 600
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 600 mg
Trial: 14962821
Drug: Rifapentine 900
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 900 mg
Trial: 14962821
Drug: Rifapentine 1200
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 1200 mg
Trial: 14962821
Drug: Rifapentine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifapentine (all doses)
Trial: 11856080
Drug: Balsalazide, 6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsalazide, 6.75 g
Trial: 11856080
Drug: Sulfasalazine, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine, 3 g
Trial: 8711365
Drug: Polyene phosphatidylcholine
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyene phosphatidylcholine (PPC) 2.7 g daily for three months
Trial: 335247
Drug: Aspirin 600
RxNorm normalized name: aspirin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 600 mg given twice daily
Trial: 24325795
Drug: High intensity,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity, 40 s, buccal
Trial: 22336009
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (SCIT) with Alutard SQ, ALK-Abell¨®
Trial: 22336009
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with Chanllergen-Df drops, Wolwo Pharma
Trial: 17999779
Drug: N-acetylcysteine (NAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC 1.8 g.day(‐1), 3 days)
Trial: 17999779
Drug: alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-lipoic acid (LIP 1.2 g.day(‐1), 3 days)
Trial: 17999779
Drug: taurine (TAU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taurine (TAU 3 g.day(‐1), 3 days)
Trial: 15697072
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg three times daily
Trial: 11696874
Drug: Inhaled iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled iron oxide particles with high soluble iron content
Trial: 11696874
Drug: Inhaled iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled iron oxide particles with low soluble iron content
Trial: 11696874
Drug: Inhaled iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled iron oxide particles (both high and low soluble iron)
Trial: 20629971
Drug: D+/R- combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D+/R- combination
Trial: 1593749
Drug: Pimobendan (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimobendan (2.5 mg, intravenous)
Trial: 1593749
Drug: Captopril (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5 mg, orally)
Trial: 6321686
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus tamoxifen (20 mg/m2 on days 2-6) and premarin (0.625 mg every 12 hours for three days on day 7)
Trial: 6321686
Drug: Chemotherapy (cytoxan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cytoxan 750 mg/m2 and Adriamycin 30 mg/m2 on day 1 plus 5‐fluorouracil 500 mg/m2 and methotrexate 40 mg/m2 on day 8)
Trial: 26516308
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 30 mg/kg followed by 10 mg/kg/h continuous infusion until the end of surgery
Trial: 21291422
Drug: Propofol treatment
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol treatment (group P)
Trial: 21291422
Drug: Isoflurane treatment
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoflurane treatment (group I)
Trial: 17121064
Drug: Sertaconazole nitrate
RxNorm normalized name: Sertaconazole Nitrate
DrugBank: Sertaconazole (DB01153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertaconazole nitrate cream 2% applied twice daily for 4 weeks
Trial: 17121064
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control applied twice daily for 4 weeks
Trial: 12734156
Drug: Morphine PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine PCA alone (Group I, n = 15)
Trial: 12734156
Drug: Morphine PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine PCA plus a continuous basal infusion (Group II, n = 14)
Trial: 10348755
Drug: Delavirdine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delavirdine monotherapy (low target arm)
Trial: 10348755
Drug: Delavirdine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delavirdine monotherapy (middle target arm)
Trial: 10348755
Drug: Delavirdine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delavirdine monotherapy (high target arm)
Trial: 10348755
Drug: Delavirdine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delavirdine monotherapy (pooled arms)
Trial: 10348755
Drug: Nucleoside control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside control therapy (zidovudine or didanosine)
Trial: 8664036
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) 200 or 300 mg/m2/day by prolonged ambulatory infusion with radiotherapy (60-66 Gy)
Trial: 1960007
Drug: High-dose yohimbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose yohimbine (peak dose, 43 mg/day)
Trial: 6264376
Drug: Glucose-containing oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-containing oral rehydration solution
Trial: 6264376
Drug: Sucrose-containing oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose-containing oral rehydration solution
Trial: 6264376
Drug: Both glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both glucose and sucrose solutions
Trial: 6500778
Drug: Vincamine teprosilate
RxNorm normalized name: vincamine
DrugBank: Vincamine (DB13374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincamine teprosilate (Teproside) at 120 mg daily for 90 days
Trial: 30157910
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZA) alongside chemotherapy
Trial: 30157910
Drug: Placebo alongside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo alongside chemotherapy
Trial: 30157910
Drug: Non-randomised open-label
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-randomised open-label arm (ZA or placebo for those who decline chemotherapy)
Trial: 20423524
Drug: Telephone-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based intervention consisting of print resources and four weekly 30-minute telephone support calls.
Trial: 16140526
Drug: Amifostine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (500 mg subcutaneously)